Parenteral Antibacterial Agents

PreclinicalSmall molecule

Parenteral Antibacterial Agents is one of 4 small molecule programs targeting ACL Reconstruction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ACL ReconstructionRecruiting

ACL ReconstructionPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in ACL Reconstruction

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

1 2

Leukocyte-Poor Platelet Rich Plasma

QQueen Savang Vadhana Memorial Hospital, Thailand

Phase 2

1 3

Bone Marrow Concentrate

IIstituto Ortopedico Rizzoli

Phase 2

1 4

Parenteral Antibacterial Agents

UUniversity of Duhok

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ACL Reconstruction1 trial

Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction

Recruiting·UUniversity of Duhok·N/A·NCT06166381·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Parenteral Antibacterial Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Parenteral Antibacterial Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Parenteral Antibacterial Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Duhok company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Duhok

Parenteral Antibacterial Agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ACL Reconstruction1 trial

References

Drug Info

Quick Facts

Related News